Overview

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Criteria
Inclusion Criteria:

- Have a body mass index (BMI) greater than or equal to 27.0 kilogram/square meter (kg/m
²)

- Have Type 2 Diabetes (T2D)

- Are on stable treatment for T2D for at least 90 days

- Have a history of at least one unsuccessful dietary effort to lose body weight.

GSA2 Inclusion Criteria

- Previously diagnosed with OSA

- Have AHI ≥15 on polysomnography at screening (definition of moderate-to-severe OSA)

- For participants not on positive airway pressure (PAP) therapy: unable or unwilling to
use PAP therapy and have not used PAP for at least 4 weeks prior to screening.

- If on PAP therapy, have been on PAP therapy for at least 3 consecutive months prior to
screening, and willing to temporarily stop using PAP therapy for approximately 7 days
prior to each of the sleep study (PSG) visits.

Exclusion Criteria:

- Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90
days.

- Have taken weight loss drugs, including over-the-counter medications, within 90 days
prior to screening.

- Have a prior or planned surgical treatment for obesity.

- Have Type 1 diabetes

- Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple
endocrine neoplasia syndrome type 2 (MEN-2)

- Have had pancreatitis

GSA2 Exclusion Criteria

- Use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant,
amphetamine) less than 3 months prior to screening.

- Use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months
prior to screening.

- Use a dental appliance or other device to treat OSA other than PAP therapy.